DZ Bank’s Royalty Pharma RPRX Stock Holding History

DZ Bank’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,200	Closed	-$90.5K	–	1019
2024 Q3	$90.5K	Buy	3,200 +2,400	+300%	+$66.5K	﹤0.01%	905
2024 Q2	$21.1K	Hold	800	–	–	﹤0.01%	991
2024 Q1	$24.3K	Hold	800	–	–	﹤0.01%	994
2023 Q4	$22.5K	Sell	800 -102,012	-99%	-$2.8M	﹤0.01%	966
2023 Q3	$2.79M	Buy	102,812 +102,012	+12,752%	+$3.03M	﹤0.01%	519
2023 Q2	$24.6K	Hold	800	–	–	﹤0.01%	968
2023 Q1	$28.8K	Hold	800	–	–	﹤0.01%	987
2022 Q4	$31.6K	Hold	800	–	–	﹤0.01%	983
2022 Q3	$32.1K	Hold	800	–	–	﹤0.01%	974
2022 Q2	$33.6K	Buy	+800	New	+$32.8K	﹤0.01%	978
2021 Q2	–	Sell	-24,521	Closed	-$1.07M	–	989
2021 Q1	$1.07M	Sell	24,521 -105,679	-81%	-$5.01M	﹤0.01%	631
2020 Q4	$6.44M	Buy	+130,200	New	+$5.52M	0.01%	401

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank's RPRX Position: Q4 2024 in Review

DZ Bank sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 3,200 shares — an estimated $90.5K sold.

DZ Bank first reported a position in RPRX in Q4 2020 and held it in 12 quarters. The position peaked at $6.44M in Q4 2020. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

DZ Bank reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
DZ Bank sold 3,200 Royalty Pharma shares in Q4 2024, an estimated $90.5K.
DZ Bank first reported a position in Royalty Pharma in Q4 2020 and held it in 12 quarters.
DZ Bank's Royalty Pharma position peaked at $6.44M in Q4 2020.
417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on DZ Bank's 13F filing for Q4 2024, filed 14 Feb 2025.